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S U M M A R Y
Objectives: To evaluate risk factors, diagnostic procedures, and treatment outcomes of invasive
aspergillosis (IA) in patients with hematological malignancies.
Methods: A retrospective analysis of data from proven/probable IA cases that occurred from 2005 to
2009 at 10 hematology centers was performed.
Results: We identiﬁed 176 IA cases that mainly occurred in patients with acute leukemias (58.5%),
mostly those on induction/re-induction treatments (39.8%). Prolonged neutropenia was the most
frequent risk factor for IA (61.4%). The lungs were the most frequently affected site (93.8%) and computed
tomography detected abnormalities in all episodes; however, only 53.7% of patients had ﬁndings
suggestive of IA. Galactomannan (GM) detection in serum or bronchoalveolar lavage ﬂuid (positive in
79.1% and 78.8% of episodes, respectively) played a crucial role in IA diagnosis. Neutrophil count and
antifungal prophylaxis did not inﬂuence the GM positivity rate, but empirical therapy decreased this rate
(in serum). Of the IA cases, 53.2% responded to initial antifungal therapy. The combination of
voriconazole and echinocandin, even as initial or salvage therapy, did not perform better than
voriconazole monotherapy (p = 0.924 for initial therapy and p = 0.205 for salvage therapy). Neutrophil
recovery had a signiﬁcant role in the response to initial (but not salvage) antifungal therapy.
Conclusions: Our retrospective analysis identiﬁed key diagnostic and treatment characteristics, and this
understanding could improve the management of hematological malignancy patients with IA.
 2012 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Invasive fungal diseases (IFD) are an important cause of
morbidity and mortality in patients with hematological diseases.1,2
The epidemiology of IFD in this group of severely immunocom-
promised patients has changed substantially during the last two* Corresponding author. Tel.: +420 602 564011.
E-mail address: zracil@fnbrno.cz (Z. Racil).
1201-9712/$36.00 – see front matter  2012 Published by Elsevier Ltd on behalf of In
http://dx.doi.org/10.1016/j.ijid.2012.09.004decades, with invasive aspergillosis (IA) being a predominant
infection.1 The incidence of this infection can vary and is mainly
based on the underlying hematological malignancy; it can reach up
to 10% among patients undergoing treatment for acute leukemia or
allogeneic hematopoietic stem cell transplantation (HSCT).3
However, there have been several key advancements over the
past decade that have signiﬁcantly improved not only the
diagnosis (widespread availability of high-resolution computed
tomography (HRCT) and non-culture based diagnostic tools, such
as the detection of galactomannan (GM)), but also treatmentternational Society for Infectious Diseases.
Table 1
Baseline characteristics
Patients
No. of patients 176
Age, years, median (range) 56 (3–77)
Sex, male/female, n (%) 104 (59.1%)/
72 (40.9%)
Patient’s disease at baseline, n (%)
AML + MDS 73 (41.5%)
ALL 30 (17.0%)
NHL + HL 27 (15.3%)
CLL 20 (11.4%)
MM 12 (6.8%)
CML + CMPD 4 (2.3%)
Other 10 (5.7%)
Anticancer therapy during/before IA, n (%)
Induction/reinduction therapy of acute leukemia 70 (39.8%)
Allogeneic HSCT 30 (17.0%)
Autologous HSCT 17 (9.7%)
Other 52 (29.5%)
None 7 (4.0%)
Presence of risk factors for development of IA, n (%)
Neutropenia <0.5  109/l for >10 days 108 (61.4%)
Administration of corticosteroids for >21 days 50 (28.4%)
Pulmonary/respiratory tract disease in anamnesis
(COPD, etc.)
22 (12.5%)
GVHD 20 (11.4%)
Other risk factors 41 (23.3%)
Number of risk factors present at diagnosis, n (%)
0 29 (16.5%)
1 79 (44.9%)
2 44 (25.0%)
3 24 (13.6%)
IA episodes
No. of episodes 176
Certainty of diagnosis according to EORTC/MSG 2002 criteria, n (%)
Proven IA 27 (15.3%)
Probable IA 149 (84.7%)
Site of infection, n (%)
Lung 165 (93.8%)
Sinuses 1 (0.6%)
Disseminated 7 (4.0%)
Other 3 (1.7%)
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic
lymphocytic leukemia; CML, chronic myeloid leukemia; CMPD, chronic myelopro-
liferative disease; COPD, chronic obstructive pulmonary disease; EORTC/MSG,
European Organisation for Research and Treatment of Cancer/Mycoses Study
Group; GVHD, graft-versus-host disease; HL, Hodgkin lymphoma; HSCT, hemato-
poietic stem cell transplantation; IA, invasive aspergillosis; MDS, myelodysplastic
syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma.
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echinocandins) of IA. These events have led to the recently
reported improvement in the prognosis of patients with this life-
threatening infection.2,4,5 Moreover, several observational regis-
tries in Europe, as well as worldwide, have been created with the
goal of collecting real world data regarding incidence, risk factors,
and treatment outcomes of patients with IA.1,2,4–6
In this multicenter study, we report data from IA episodes that
occurred in patients with hematological malignancies. These data
were retrospectively collected from the Fungal InfectioN Database
(FIND), which holds data from almost all hematology centers in the
Czech and Slovak republics. The aim of this study was to analyze
the risk factors, diagnostic procedures, and treatment outcomes
from the largest cohort of IA episodes in Central Europe published
to date.
2. Methods
2.1. Design
Thirteen hematology centers in the Czech and Slovak republics
participate in the FIND project. The database consists of
retrospectively collected data of proven and probable IA cases
that occurred between 2001 and 2009, as well as a prospective
collection of cases from 2010 onwards.
This study was conducted by performing an analysis of proven
and probable IA cases that occurred between January 1, 2005 and
December 31, 2009, which had been retrospectively entered as
electronic case report forms by 10 of 13 participating centers
(seven adult and three pediatric centers). The distribution of
episodes during this time period was not uniform and was mainly
dependent on the extension of non-culture-based diagnostic
techniques (e.g., GM detection) among centers. Therefore, the
number of episodes in individual time intervals does not reﬂect the
real incidence of infection. Forty-one percent of cases entered into
the database and analyzed occurred between 2005 and 2007, 59%
between 2008 and 2009.
2.2. Case identiﬁcation
Cases were identiﬁed in participating centers by reviewing the
patient charts as well as laboratory, microbiology, and imaging
results. Pathology reports from autopsies were also used. All
identiﬁed episodes of IA during the observation period were
included in the database.
The variables collected in the electronic case report forms
included the subject’s demographic characteristics, underlying
hematological malignancy and treatment, clinical signs and
symptoms, and the results of microbiological and histological
investigations, as well as results of imaging studies, information
regarding the use of mold-active antifungal prophylaxis and
empirical antifungal treatment, targeted antifungal treatment and
outcomes, neutrophil counts at the time of diagnosis as well as
before and after each antifungal treatment, and ﬁnally patient
survival. Due to the retrospective design of this study, a patient’s
informed consent was not required. The Institutional Review Board
of the University Hospital Brno approved this study.
2.3. Deﬁnitions
Episodes of IA were deﬁned according to the 2002 European
Organisation for Research and Treatment of Cancer and Mycosis
Study Group (EORTC/MSG) criteria.7 The day of diagnosis was
deﬁned as the day when criteria for proven or probable IA were
fulﬁlled. Empirical antifungal therapy was deﬁned as the
administration of systemic antifungal treatment in patients withpersistent fever only, or in patients who did not fulﬁll criteria for
proven or probable IFD at the time of treatment initiation. Targeted
antifungal therapy was started when patients fulﬁlled criteria for
proven or probable IA. The overall outcome of therapy, as well as
the outcome of each line of antifungal treatment, was classiﬁed
according to published EORTC/MSG recommendations.8 The effect
of therapy was evaluated only if the targeted antifungal therapy
lasted at least 5 days. An independent, blinded evaluation of all the
entered data was performed by a review board at the main study
center, with special consideration to the fulﬁllment of EORTC/MSG
criteria for the diagnosis of proven or probable IA, as well as
treatment outcome.
2.4. Statistical analysis
Frequency tables and standard descriptive statistics were used
for summation of the patient characteristics. Proportions were
compared with the maximum-likelihood Chi-square test or
Fisher’s exact test. Continuous variables were compared with
the Mann–Whitney or Kruskal–Wallis analysis of variance
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were estimated using the Kaplan–Meier method, and a comparison
of survival in the groups of patients was performed using a log-
rank test. The point estimates were supplied with 95% conﬁdence
intervals (CI). A level of statistical signiﬁcance a = 0.05 was used in
all analyses. For the analysis of the role of neutrophil count at the
deﬁned time points in the efﬁcacy of antifungal treatment, patients
were divided into three groups: those with a neutrophil count
0.1, 0.1–1.0, and 1.0  109/l. Analyses were performed using
statistical software SPSS 12.0.2 for Windows (SPSS Inc., 2003) and
STATISTICA 9.0.1 for Windows (StatSoft, Inc. 2010).
3. Results
3.1. Characteristics of patients and episodes of IA
During the study period (2005–2009), 176 episodes of IA
occurring in 176 patients were identiﬁed: 27 (15.3%) proven and
149 (84.7%) probable. Patient characteristics are shown in Table 1.
Acute leukemias represented the majority of the underlying
hematological diseases (58.5%), and induction or re-induction
treatment for acute leukemia (but not allogeneic HSCT) repre-
sented the most frequent anticancer treatment (39.8%). Therefore,
patients with active acute leukemia during the ﬁrst induction or
salvage therapy represented the typical population of hemato-
logical malignancy patients with the highest risk of IA. Based on
these data, it is not surprising that the most common classical risk
factor identiﬁed in 61.4% of IA episodes was profound andTable 2
Clinical manifestations and results of diagnostic tests at the time of diagnosis of invas
Clinical manifestations at the time of diagnosis, all patients (N = 176), n (%)
Fever >38.0 8C 
Fever not responding to 5 days of antibiotics 
Presence of organ-speciﬁc clinical symptoms 
Clinical signs in patients with IPA (n = 165), n (%)
Any symptom 
Cough 
Dyspnea 
Chest pain 
Hemoptysis 
Other 
Chest X-ray abnormality in patients with IPA (n = 152),a n (%)
Any abnormality 
Non-speciﬁc inﬁltrate(s) 
Nodule(s) 
Interstitial process 
Pleural effusion 
Cavitation(s) 
Other 
Chest high-resolution CT abnormality in patients with IPA (n = 149),a n (%)
Any abnormality 
Predominant abnormality
Non-speciﬁc inﬁltrate(s) 
Halo sign 
Macronodule(s) >1 cm 
Cavitation 
Micronodule(s) <1 cm 
Pleural effusion 
Air crescent sign 
Laboratory test results at the time of diagnosis, all patients, n (%)
Serum galactomannan positive (consecutive index of positivity >0.5) (n = 172)a
Serum (1!3)-b-D-glucan positive (single value >80 pg/ml) (n = 44)a
Mycological examination, microscopy positive (all materials) (n = 71)a
Mycological examination, culture positive (all materials) (n = 81)a
Histology positive (all materials) (n = 12)a
BAL ﬂuid examination in patients with IPA, n (%)
Mycological examination, microscopy positive (n = 49)a
Mycological examination, culture positive (n = 48)a
BAL ﬂuid galactomannan positive (index of positivity >0.5) (n = 66)a
BAL, bronchoalveolar lavage; CT, computed tomography; IPA, invasive pulmonary aspe
a Calculated only for patients for whom the test was performed.prolonged neutropenia (Table 1). The lung was the most
commonly affected site (93.8%), with 21 (12.0%) proven and
144 (81.8%) probable episodes. In addition, disseminated and
isolated extrapulmonary infections were rare (4.0% and 2.3%,
respectively).
3.2. Signs of infection
Out of the 176 patients with IA, 136 (77.3%) had fever at the
time of diagnosis, with a median duration of 6 days before
diagnosis (range 0–53 days before diagnosis; interquartile range
(IQR) 3–11 days before diagnosis). Moreover, 54.0% of patients
with IA fulﬁlled criteria for persistent fever despite the adminis-
tration of broad-spectrum antibiotics for 5 days. Out of
165 patients with invasive pulmonary aspergillosis (IPA), 125
(75.8%) exhibited at least one sign that was suggestive of
pulmonary disease, which developed within a median of 5 days
before diagnosis (range 0–35 days; IQR 2–9 days). The spectrum of
these signs is shown in Table 2.
3.3. Diagnostic procedures
3.3.1. Imaging studies
A chest X-ray was performed at the time of diagnosis in 152/165
(92.1%) patients with IPA. However, abnormalities were only
identiﬁed in 73.0% of those patients. Moreover, the most
commonly observed abnormality was a non-speciﬁc inﬁltrate
(44.7%) (Table 2). In contrast, chest HRCT, which was performedive aspergillosis
136 (77.3%)
95 (54.0%)
134 (76.1%)
125 (75.8%)
69 (41.8%)
37 (22.4%)
11 (6.7%)
2 (1.2%)
6 (3.6%)
111 (73.0%)
68 (44.7%)
36 (23.7%)
1 (0.7%)
1 (0.7%)
1 (0.7%)
4 (2.6%)
149 (100%)
69 (46.3%)
40 (26.8%)
17 (11.4%)
9 (6.0%)
8 (5.4%)
5 (3.4%)
1 (0.7%)
136 (79.1%)
36 (81.8%)
9 (12.7%)
24 (29.6%)
8 (66.7%)
5 (10.2%)
9 (18.8%)
52 (78.8%)
rgillosis.
Table 3
Antifungal prophylaxis and empirical antifungal therapy
Anti-mold prophylaxis at the time of IA diagnosis
Present 44 (25.0%)
Antifungal drug useda
Itraconazole 25 (56.8%)
Voriconazole 7 (15.9%)
Posaconazole 6 (13.6%)
Conventional amphotericin B 4 (9.1%)
Echinocandin 2 (4.5%)
Anti-mold empirical antifungal therapy at the time of IA diagnosis
Present 76 (43.2%)
Antifungal drug useda
Conventional amphotericin B 23 (30.3%)
Lipid formulation of amphotericin B 20 (26.3%)
Voriconazole 13 (17.1%)
Echinocandin 12 (15.8%)
Other 9 (11.8%)
IA, invasive aspergillosis.
a Percentage calculated from patients receiving treatment.
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(2005–2007, 87.8% vs. 2008–2009, 90.2%, p = 0.620), detected an
abnormality in all of these patients. Interestingly, the most
frequently observed abnormality on these early HRCT scans was a
non-speciﬁc inﬁltrate (46.3%). Signs that are more speciﬁc for IFD,
such as a halo sign, nodules, or cavitations, were seen substan-
tially less frequently (Table 2). There was no statistically
signiﬁcant difference in the frequency of individual abnormalities
on HRCT scans between patients with neutropenia (neutrophils
<1.0  109/l) and those without (p = 0.378).
3.3.2. Non-culture diagnostic techniques—serum
The GM test was performed at all centers for screening (2–3
times per week) in high-risk patients (e.g., patients receiving
induction for acute leukemia or undergoing allogeneic HSCT)
and on request in all other patients with abnormalities on
imaging studies. GM assessment of at least two serum samples
was performed in 172/176 (97.7%) patients with IA (2005–2007,
95.9% vs. 2008–2009, 99.0%, p = 0.176). Using the criterion of an
index of positivity >0.5 from two consecutive serum samples as
a positive test result, we found the test positive in 79.1% of
tested episodes (Table 2), and a positive result of the GM assay
(consecutive positivity) preceded the ﬁnal diagnosis of IA by a
median of 2 days (range 0–34 days; IQR 1–4 days). The rate of
positive test results was not inﬂuenced by the neutrophil count
at the time of diagnosis (p = 0.426) or by the administration of
mold-active antifungal prophylaxis (p = 0.854). In contrast,
empirical antifungal therapy using a mold-active antifungal
drug at the time of diagnosis of IA signiﬁcantly decreased the
proportion of positive GM test results in serum compared to
patients not receiving the treatment (67% vs. 88%, respectively;
p = 0.001). The median serum GM index of positivity level at the
time of IA diagnosis was 1.28 (range 0.11–11.46). The detection
of 1!3-b-D-glucan (BG) was available at only one center, and
therefore the test was performed in only 44/176 (25.0%)
patients. A positive test result (BG concentration >80 pg/ml
from a single serum sample as the cut-off) was recorded in 81.8%
of these patients (Table 2).
3.3.3. Mycological examination
Histological examination, microscopic evaluation, and cultures
of any relevant clinical specimens were performed in 12/176
(6.8%), 71/176 (40.3%), and 81/176 (46.0%) patients with IA,
respectively. However, with the exception of the histological
examination, which was positive in 66.7% of a very limited number
of samples obtained by biopsy, the rate of positive results of the
other two conventional techniques was very low (12.7% and 29.6%,
respectively) (Table 2).
Aspergillus fumigatus represented 19/24 (79.2%) identiﬁed
isolates, followed by Aspergillus ﬂavus 1/24 (4.2%), Aspergillus niger
1/24 (4.2%), Aspergillus terreus 1/24 (4.2%), and other Aspergillus
species 2/24 (8.3%).
3.3.4. Bronchoalveolar lavage (BAL) ﬂuid analysis
Since IPA predominated in our patient group, BAL ﬂuid was the
most frequent mycologically evaluated material (Table 2).
However, conventional mycological techniques with a very low
frequency of positive results (10.2% microscopy and 18.8% culture)
did not contribute substantially to the diagnosis of IPA in this
group of patients. In contrast, the GM assay was positive in 52 out
of 66 (78.8%) obtained BAL ﬂuids using a cut-off value of 0.5. The
rate of GM assay positivity in BAL ﬂuid was not inﬂuenced by
neutrophil count (p = 0.580) or the administration of mold-active
antifungal prophylaxis (p = 0.147), and in contrast to serum was
not inﬂuenced by empirical antifungal therapy (76% vs. 81%;
p = 0.607).3.4. Prophylaxis and empirical treatment
Of the 176 patients with IA, 44 (25.0%) had received mold-active
antifungal prophylaxis, with a median treatment time of 24 days
(range 4–227 days; IQR 16–42 days) (Table 3). More than half of
these episodes developed under prophylaxis treatment with
itraconazole (25/44, 56.8%); however, itraconazole was also the
most frequently used anti-mold prophylaxis at the time our study
was performed. Moreover, the azole plasma concentration before
breakthrough infection was only available in two patients.
At the time of diagnosis of IA, 76/176 (43.2%) patients had
already received mold-active empirical antifungal treatment, and
the most frequently used was conventional amphotericin B (30.3%
of empirically treated patients) (Table 3). The length of empirical
treatment before the deﬁnitive diagnosis of IA was short (median 6
days, range 2–44 days, IQR 4–11 days). Therefore, this relatively
high number of empirically treated patients reﬂects the suspicions
of the clinician to IFD and early administration of systemic
antifungals, rather than a high number of breakthrough IFD cases
during prolonged antifungal therapy.
3.5. Antifungal therapy
Targeted antifungal therapy for proven and probable IA was
administered in 156/176 (88.6%) patients. In addition, 71 (40.3%)
patients received only one line of therapy, 61 (34.7%) patients
received treatment with a second-line therapy for toxicity or
failure of the previous therapy, and 24 (13.6%) patients received
more than two lines of antifungal therapy. Neither the spectrum of
antifungal drugs nor their combinations used for the treatment of
IA differed between the two observed periods (p = 0.252, p = 0.229,
and p = 0.622, for ﬁrst line, second line, and further lines,
respectively).
A complete or partial response to treatment was achieved in
83/156 (53.2%) patients treated with ﬁrst-line therapy (median
length of ﬁrst-line therapy 15 days, range 5–139 days, IQR 10–
25 days). There was no substantial difference in the response
rate between the two most frequently used approaches:
voriconazole monotherapy and a combination of voriconazole
and echinocandin (61.9% vs. 61.0%, respectively; p = 0.924)
(Table 4). Forty (25.6%) of the 156 patients treated with ﬁrst-
line therapy received salvage therapy for failure of this
treatment (median duration 19 days, range 5–159 days, IQR
10–32 days). Although the number of these patients was limited,
the combination of voriconazole and echinocandin did not
provide a better therapeutic outcome in this setting compared to
voriconazole monotherapy (p = 0.205) (Table 4).
Table 4
Targeted antifungal therapy—efﬁcacy of ﬁrst-line and salvage therapy
Treatment response
n Complete or
partial response
Stable disease Progression Not known
First-line therapy 156 83 (53.2%) 20 (12.8%) 53 (34.0%) -
Voriconazole 63 39 (61.9%) 8 (12.7%) 16 (25.4%) -
Combination of echinocandin + voriconazole 41 25 (61.0%) 3 (7.3%) 13 (31.7%) -
Conventional AMB 13 4 (30.8%) 3 (23.1%) 6 (46.2%) -
Lipid formulation of AMB 13 7 (53.8%) 1 (7.7%) 5 (38.5%) -
Echinocandin 9 2 (22.2%) - 7 (77.8%) -
Other 17 6 (35.3%) 5 (29.4%) 6 (35.3%) -
Salvage therapy 40 15 (37.5%) 7 (17.5%) 17 (42.5%) 1 (2.5%)
Voriconazole 9 2 (22.2%) 3 (33.3%) 3 (33.3%) 1 (11.1%)
Combination of echinocandin + voriconazole 7 4 (57.1%) 2 (28.6%) 1 (14.3%) -
Lipid formulation of AMB 3 1 (33.3%) 1 (33.3%) 1 (33.3%) -
Other 21 8 (38.1%) 1 (4.8%) 12 (57.1%) -
AMB, amphotericin B.
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received granulocyte colony stimulating factors. Granulocyte
transfusions were not used. Of the 176 patients, 10 (5.7%)
underwent surgery in addition to chemotherapy.
At the end of all targeted treatment approaches efﬁcacy was
evaluated. The median length of treatment was 32.5 days (range 5–
148 days, IQR 17–66 days), and 105 out of 156 (67.3%) patients
responded; however, 50/156 (32.1%) patients failed and one
patient was not evaluable. Secondary prophylaxis (mostly with
voriconazole) was used in 71/176 (40.3%) patients with a
median length of treatment of 48 days (range 10–512 days; IQR
21–78 days).
3.6. The role of neutrophils in the efﬁcacy of antifungal treatment
There was no statistically signiﬁcant difference in the percent-
age of patients with a successful treatment outcome (complete and
partial response) at the end of all antifungal therapies based on
neutrophil count at the start of antifungal treatment (p = 0.423).
This lack of difference was also found when the role of neutrophils
at the start of the ﬁrst treatment and salvage therapy and the
treatment outcome at the end of these therapies was evaluated
separately (Table 5).
In contrast, there was a statistically signiﬁcant increase in the
percentage of patients who successfully responded (complete and
partial response) at the end of all antifungal therapies with
increasing neutrophil counts at the end of antifungal treatment
(p < 0.001) (Table 5). A substantially higher response rate was
identiﬁed in patients with neutrophil counts >1.0  109/l at theTable 5
The role of neutrophil count at the start and at the end of antifungal therapy in treatm
Patients with successful treatmen
Neutrophils
<0.1  109/l
Neutrophil count at the start of:
Any therapy (n = 143) 63.8% 
First-line therapy (n = 144) 50.7% 
Salvage therapyc (n = 30) 37.5% 
Neutrophil count at the end of:
All therapies (n = 128) 21.1% 
First-line therapy (n = 129) 16.7% 
Salvage therapyc (n = 32) 20.0% 
a The treatment outcome was evaluated at the end of therapy given in the raw (i.e., t
therapy, respectively).
b Maximum-likelihood Chi-square test, difference between all three groups accordin
c Salvage was deﬁned as treatment after failure of ﬁrst-line therapy.end of the ﬁrst-line treatment compared to patients with
neutrophil counts of 0.1–1.0 (p = 0.007) and <0.1 (p < 0.001) 
109/l. However, we did not ﬁnd a role of neutrophil counts at the
end of salvage therapy in patients receiving this treatment
(p = 0.432) (Table 5).
Finally, the change in neutrophil count during IA therapy and
treatment outcome was analyzed. During ﬁrst-line treatment,
patients with a successful treatment outcome (complete and
partial response of IA) had a signiﬁcant increase in neutrophil
count (p < 0.001 and p = 0.003, respectively). Moreover, the
median neutrophil count in patients with a complete or partial
response increased during the treatment from neutropenic range
(<1.0  109/l) to non-neutropenic range (Figure 1A). In contrast,
patients with treatment failure were persistently neutropenic
(progression of IA) or did not reveal any signiﬁcant increase in their
neutrophil count during therapy (stable IA) (Figure 1A). A similar
analysis was performed for patients receiving salvage therapy, and
no signiﬁcant increase in neutrophil count was observed in any
treatment outcome group (Figure 1B); however, the number of
patients was limited.
3.7. Survival
The median survival in our patient group was 28.1 (95% CI 15.6–
40.7) weeks. The 3- and 12-month overall survival (OS) was 57.8%
(95% CI 50.5–65.1%) and 43.0% (95% CI 35.4–50.5%), respectively.
OS follows survival attributed to IA (OSIA), thus IA was the
predominant cause of death during the ﬁrst 3 months after
diagnosis, while other causes (mainly underlying diseases) wereent outcome
t outcome (complete or partial response) at the end of therapy (%)a
Neutrophils
0.1–1.0  109/l
Neutrophils
>1.0  109/l
p-Valueb
76.7% 70.5% 0.423
53.3% 64.4% 0.341
66.7% 25.0% 0.195
50.0% 80.9% <0.001
35.0% 68.2% <0.001
57.1% 40.0% 0.432
he end of all received therapies, the end of ﬁrst-line therapy, or the end of salvage
g to neutrophil count.
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Figure 1. Change in neutrophil count during (A) ﬁrst-line and (B) salvage therapy of invasive aspergillosis (CR, complete response; PR, partial response; SD, stable disease).
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longer than 3 months (Figure 2A). Patients with probable IA had
signiﬁcantly better OS as well as survival attributed to IA (OSIA)
(Figure 2B). OS as well as OSIA did not differ between cases
diagnosed during 2005–2007 compared to more recent episodes
(2008–2009) (OS: p = 0.173, 63.4% (95% CI 52.4–74.4%) vs. 52.7%
(95% CI 42.9–62.4%) at 3 months, respectively; OSIA: p = 0.366,
70.7% (95% CI 60.1–81.3%) vs. 60.8% (95% CI 51.0–70.6%) at
3 months, respectively).
4. Discussion
This is the largest multicenter study published to date that has
analyzed episodes of IA in hematological malignancy patients from
Central Europe. FIND is a network of hematology centers that
gather and share information to improve our understanding of
epidemiology, diagnostics, therapy, and the outcome of IFD inhematological malignancy patients from the Czech and Slovak
republics.
Our analysis conﬁrmed several published and generally
accepted facts in the view of risk factors, diagnostics, and
treatment of this infection among patients with hematological
malignancies.2,4,6,9–16
The signiﬁcance of our study clearly lies in several unique
ﬁndings, which should be noted. First, although we have shown the
importance of using early lung HRCT for the diagnosis of
pulmonary abnormalities (all patients with IPA had some
detectable abnormality), only 53.7% had ﬁndings that were
described as ‘speciﬁc’ for invasive mold infection based on
EORTC/MSG 2008 criteria.17 Therefore, half of our IPA patients
had non-speciﬁc inﬁltrates on early HRCT scans, of which the
performance was generally driven by persistent fever or GM
results. Recent studies have shown that the neutrophil count plays
a role in the pattern of ﬁndings on imaging studies.11,18 However,
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Figure 2. Overall survival and survival attributed to invasive aspergillosis (IA) for (A) all patients and (B) based on the probability of IA diagnosis.
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patient population and percentage of patients with prolonged
neutropenia was similar to our observations in this analysis.
However, the authors of that study found a ‘halo sign’ in 81% of the
patients, whereas only 26.8% of patients had the sign in our study.
On the other hand, a recent study by Lortholary et al.6 examining a
mixed patient population with 77.6% of patients suffering from a
hematological malignancy found nodules in the majority of
patients (81.3%) with IPA. However, nodules were again rarely
found in our study (16.8%). Moreover, we did not observe any
signiﬁcant difference in the frequency of individual abnormalities,
including the frequency of non-speciﬁc inﬁltrates in patients withand without neutropenia. Therefore, despite the multicenter
approach whereby CT evaluations were performed by local
radiologists, one of the explanations for the signiﬁcant proportion
of non-speciﬁc ﬁndings could be the promptitude of HRCT usage in
patients with persistent fever or GM positivity, which has been
seen in the last few years due to better availability of this
technique. The median time from an HRCT scan to diagnosis of IA in
our study was 0 days. Thus, in daily clinical practice where early CT
scans are commonly performed and non-speciﬁc inﬁltrates are
more frequently seen, mycological examination of these non-
speciﬁc lesions for a differential diagnosis becomes very impor-
tant. This ﬁnding was very recently supported by others.19,20
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the diagnosis of IA.21 Since the vast majority of cases represented
probable IA and the sensitivity of culture and/or cytology was very
limited, the diagnosis of probable IA was typically made using a
combination of pulmonary abnormalities on lung HRCT and
positivity of a GM assay with serum and/or BAL ﬂuid. In addition,
the high rate of positive results of the GM assay in serum (79.1%)
and BAL ﬂuid (78.8%) was similar or higher than in a recently
published series of hematological patients.4,6,22
This multicenter study also found that the routine use of regular
and frequent (2–3/week) GM screening is widely used at all
hematology centers in both countries and seems common in the
countries of Europe,4,6 but is less frequent or limited in others
countries,9 including the USA.5 Therefore, GM screening was often
used in place of invasive procedures for the differential diagnosis of
pulmonary inﬁltrates. In a study by Perkhofer et al.9 conducted in
Austria, 34% of the patients with invasive mold infections had a
biopsy performed, whereas only 9.6% of the patients in our study
required a biopsy for ﬁnal diagnosis. The authors of that study
recommend performing biopsies in these patients due to the high
frequency of invasive zygomycosis. However, the high rate of
positive results of the GM assay (serum and/or BAL) in our study
could limit biopsies to only GM-negative inﬁltrates that are very
likely to be of IFD origin. Another reason for performing a biopsy
given by Perkhofer et al. is the requirement for culture veriﬁcation
of the infection due to the high frequency of A. terreus cases;
A. terreus is resistant to amphotericin B.9,23 However, in our study,
A. fumigatus was still the predominant species, and non-fumigatus
Aspergillus species were very rare, with A. terreus isolated in only
one case from our large multicenter series. Finally, the importance
of GM detection for the diagnosis of IA in daily clinical practice was
demonstrated based on the investigator’s questionnaire, which is
part of our database (data not shown). In 60.2% of IA episodes,
investigators subjectively marked the GM assay result as the
criterion on which the IA diagnosis was mainly based, followed by
HRCT in 18.8% of episodes and histology in 10.2% of episodes.
However, when discussing GM assay results, the possible
limitation of the test (extensively reviewed in the last European
Conference on Infections in Leukemia (ECIL-3) recommenda-
tions24) given by the risk of lower sensitivity (e.g., caused by
administration of mold-active antifungal drugs) or by false-
positive results must always be taken into account.
Regardless of recently published and generally accepted
guidelines,25 26.3% of patients with IA in our database received
a combination antifungal treatment, which was mainly a
combination of voriconazole and echinocandin, as an initial
therapy of IA. This ﬁnding, which has also been reported in other
registries,9,26 reﬂects the real-life situation, where the treating
physician intends to maximize the efﬁcacy of antifungal treatment
in this group of highly immunocompromised and frequently
critically ill patients, not only at the time when the initial
treatment fails, but ideally at the start of therapy. However,
regardless of promising results from in vitro27,28 and animal
studies,29 there is limited evidence for such an approach in the
salvage setting,30,31 and more in the initial treatment32,33 of IA in
the literature. Although our study was retrospective and not
randomized, we did not ﬁnd any difference in the efﬁcacy of
voriconazole monotherapy compared to the combination of this
azole with echinocandin when used as an initial or salvage therapy.
The number of patients with neutropenia (<1.0  109/l) and the
length of therapy were not different between treatment groups.
However, we did not collect information about performance status,
and therefore we cannot exclude the possibility that patients with
a severe clinical condition did not preferentially receive a
combination therapy, at least during the initial treatment.
Therefore, in order to ﬁnally resolve this issue, we should awaitthe results of randomized studies comparing both of these
approaches that are currently being conducted.
Finally, even with the availability of new antifungal therapies, a
large number of patients still fail. Therefore, the actual immuno-
deﬁciency status of each patient will play a crucial role in the
treatment outcome. Although neutropenia was the most frequent
risk factor found for the development of IA, the neutrophil level, in
addition to the antifungal therapy used for treatment, would have
an impact on patient prognosis.34 Cordonnier et al. found no
impact of neutropenia on patient prognosis at the time of IA
diagnosis.35 Similarly, in our analysis we did not ﬁnd any
signiﬁcant role of neutrophil count at the start of antifungal
therapy on the efﬁcacy of antifungal treatment (primary as well as
salvage). However, similar to data presented by Pagano et al.,2
which showed that acute myeloid leukemia patients with IA had a
higher response rate when they had neutropenic recovery, we
found a statistically signiﬁcant increase in the response rate when
the neutrophil count measured at the end of antifungal therapy
had increased, regardless of the antifungal drug used for treatment.
However, our sub-analysis found this crucial role of neutrophil
count at the end of treatment was signiﬁcant for primary therapy,
but was not signiﬁcant for salvage treatment, which was most
likely due to the limited number of patients undergoing salvage
therapy. An increase in neutrophil count greater than 1.0  109/l
during initial therapy was related to a complete and partial
response, while patients with progression remained neutropenic.
However, we found that the outcome of therapy in patients
receiving a second-line treatment may be dependent on factors
other than the development of neutrophil count during or at the
end of therapy, such as the presence of graft-versus-host disease,
persistent corticosteroid use, or hepatic insufﬁciency.34
In conclusion, IA is a life-threatening condition and the most
frequent IFD in patients with hematological malignancies that
requires rapid and speciﬁc diagnostics. Lung HRCT with high
sensitivity allows for the detection of pulmonary abnormalities;
however, these scans are often very non-speciﬁc. Therefore, the
combination of HRCT with routine and regular screening of GM in
serum and/or BAL ﬂuid provides a better differential and rapid
diagnosis of IA in this group of immunocompromised patients.
While we do not have data that clearly support the beneﬁt of
combination antifungal treatment, we have clearly shown that the
development of neutrophil count during IA treatment will be a key
factor that will determine the treatment response regardless of the
antifungal drug or strategy used.
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